Sarepta Therapeutics, Inc. SRPT Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Elevidys | $101.97M-72.8% | $110.4M-71.3% | $131.5M-27.3% | $281.85M+132% | $374.99M+4.3% | |
| Pmo Products | $228.55M-3.4% | $259.21M+2.0% | $238.55M-4.1% | $231.27M-3.2% | $236.54M+4.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Sarepta Therapeutics, Inc. break its business down?
- Sarepta Therapeutics, Inc. (SRPT) reports revenue by product across 2 parts — Elevidys and Pmo Products. Each is extracted from the segment footnotes and tracked over time.
- Where does Sarepta Therapeutics, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Sarepta Therapeutics, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.